Windlas Biotech Valuation
Is 543329 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 543329 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 543329 (₹957.95) is trading above our estimate of fair value (₹55.57)
Significantly Below Fair Value: 543329 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 543329?
Key metric: As 543329 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 543329's PE Ratio? | |
|---|---|
| PE Ratio | 32.7x |
| Earnings | ₹612.28m |
| Market Cap | ₹20.04b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | 21.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 543329's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 48.7x | ||
TARSONS Tarsons Products | 60.6x | 27.7% | ₹20.9b |
524394 Vimta Labs | 33.4x | n/a | ₹16.5b |
544184 Borosil Scientific | 55.8x | n/a | ₹16.1b |
INNOVACAP Innova Captab | 45.1x | 29.7% | ₹53.3b |
543329 Windlas Biotech | 32.7x | n/a | ₹20.0b |
Price-To-Earnings vs Peers: 543329 is good value based on its Price-To-Earnings Ratio (32.7x) compared to the peer average (48.7x).
Price to Earnings Ratio vs Industry
How does 543329's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 543329 is expensive based on its Price-To-Earnings Ratio (32.7x) compared to the Asian Life Sciences industry average (30.3x).
Price to Earnings Ratio vs Fair Ratio
What is 543329's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 32.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 543329's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Vilin Bio Med
₹313.9m
Engages in the manufacture and sale of pharmaceutical products in India.
VILINBIO
₹22.50
7D
-4.9%
1Y
2.3%
Bal Pharma
₹2.1b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹130.88
7D
9.2%
1Y
22.1%
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹926.75
7D
-2.4%
1Y
18.8%